ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07060001 (Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia), which is not on this map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07060001 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Evaluation of the Efficacy of Hypomethylating Agent Versus Standard Intensive Chemotherapy Induction Based on 5hmC - a Novel, Blood Epigenetic Marker for Assessing Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Who cites it
43 citing papers in PubMed, 116 citations in OpenAlex.
- Utilization of Brain Physiologically Based Pharmacokinetic Modeling in Support of CNS Drug Development: Case Example of Fenebrutinib.The AAPS journal · 2026Article
- Review
- Plasma cell-free DNA 5-hydroxymethylcytosine signatures as predictive biomarkers for platinum resistance and prognosis in epithelial ovarian cancer.Journal of ovarian research · 2026Article
- Natural Compounds as Epimodulators in Epithelial Ovarian Cancer.Epigenomes · 2026Review
- Inflammatory milieu and role of epigenetic modifications in high-grade serous ovarian cancer.Clinical epigenetics · 2026Review
- TCN-5mC: a predictor of 5-methylcytosine sites based on multi-feature fusion and TCN-inspired block networks.Frontiers in genetics · 2026Article
- 5-Hydroxymethylcytosine: a key epigenetic mark in cancer and chemotherapy response.Epigenetics & chromatin · 2025Review
- PRAME Expression in Melanoma is Negatively Regulated by TET2-Mediated DNA Hydroxymethylation.Laboratory investigation; a journal of technical methods and pathology · 2025Article
- Colorectal cancer progression to metastasis is associated with dynamic genome-wide biphasic 5-hydroxymethylcytosine accumulation.BMC biology · 2025Article
- PARP inhibition increases sensitivity to cisplatin in non-small-cell lung carcinoma via the induction of TET-dependent hydroxymethylation.Frontiers in cell and developmental biology · 2025Article
- 5-hydroxymethylcytosines from circulating cell-free DNA as noninvasive prognostic markers for gastric cancer.PloS one · 2025Article
- PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation.bioRxiv : the preprint server for biology · 2024Article
- 5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer.Cells · 2024Article
- Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.BMC women's health · 2024Article
- The Role of 5-Hydroxymethylcytosine as a Potential Epigenetic Biomarker in a Large Series of Thyroid Neoplasms.Endocrine pathology · 2024Article
- Article
- Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.Molecular cancer · 2023Review
- Article
- Article
- Helicobacter pylori-induced aberrant demethylation and expression of GNB4 promotes gastric carcinogenesis via the Hippo-YAP1 pathway.BMC medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 2 countries.
Douglass W TuckerDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Christopher R Getchell *Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Eric T McCarthy *Department of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Anders W OhmanDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Naoko SasamotoEpidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Shuyun XuDepartment of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Joo Yeon KoDepartment of Dermatology, Hanyang University College of Medicine, Seoul, Korea.
Mamta GuptaEpidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Amy ShafrirEpidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Jamie E MedinaDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Jonathan J LeeDepartment of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Lauren A MacDonaldDepartment of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
Ammara MalikDepartment of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
Kathleen T HasselblattGynecologic Oncology Laboratory, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts.
Wenjing LiDepartment of Medicine, Division of Endocrinology, Brigham and Women's Hospital, Harvard Medical School Boston, Massachusetts.
Hong ZhangDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Samuel J KaplanDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
George F MurphyDepartment of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Michelle S HirschDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Joyce F LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
Ursula A MatulonisDepartment of Medical Oncology, Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts.
Kathryn L TerryEpidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ddinulescu@bwh.harvard.edu cglian@bwh.harvard.edu kterry@bwh.harvard.edu.
Christine G LianDepartment of Pathology, Division of Dermatopathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ddinulescu@bwh.harvard.edu cglian@bwh.harvard.edu kterry@bwh.harvard.edu.
Daniela M DinulescuDepartment of Pathology, Division of Women's and Perinatal Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ddinulescu@bwh.harvard.edu cglian@bwh.harvard.edu kterry@bwh.harvard.edu.
Brigham and Women's Hospital · USDana-Farber Cancer Institute · USHanyang University Seoul Hospital · KR
Funding
Subcellular Enzyme-instructed self-assembly for molecular anticancer nanomedicinesR01CA142746 · NCI · BRANDEIS UNIVERSITY · PI Bing Xu · 2010 to 2026
$6.4MDefining microRNA Signatures for Early Detection in BRCA-Mutated Ovarian CancerR03CA189462 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI DINULESCU, DANIELA M · 2014 to 2015
$170kNCI NIH HHS R01 CA142746NCI NIH HHS R03 CA189462Wellcome Trust
Abstract
PubMed holds no abstract for this paper.
Indexed as
Epigenesis, Genetic5-MethylcytosineAnimalsCell SurvivalCellular ReprogrammingCombined Modality TherapyCystadenocarcinoma, SerousDioxygenasesDisease Models, AnimalDisease ProgressionDNA-Binding ProteinsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMice5-hydroxymethylcytosine5-MethylcytosineDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanTET3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07060001ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.